Ocythera Inc.

Based in Montreal, Canada, Ocythera develops innovative therapies targeting rare bone disorders through unique small molecule inhibitors, aiming to address critical medical needs in this specialized field. Ocythera, founded in 2024 by Martin Petkovich and headquartered in Montreal, Canada, focuses on therapies for rare bone disorders. As of April 2026, Joseph Mancini is the interim CEO of the company. In January 2026, Ocythera raised seed funding from adMare Bioinnovations and Investment Quebec.

Ocythera specializes in developing innovative therapies for rare bone disorders through first-in-class small molecule inhibitors that selectively target enzymes involved in bone disease pathology. The company primarily focuses on Hereditary Multiple Osteochondromas (MO) and Fibrodysplasia Ossificans Progressiva (FOP), which affect bone formation and mobility. Their compounds modulate local retinoic acid signaling pathways, offering a safer therapeutic profile. Ocythera aims to meet the unmet medical needs of patients in North America and Europe who suffer from these genetic disorders.

The company may use the January 2026 funding to accelerate Ocythera’s development of highly selective CYP26B1 inhibitors, a novel approach to treating rare bone disorders with improved safety and efficacy.